WHO ICTRP trial
Qinggan Jiangya capsule with songlingxuemaikang capsule in the treatment of…
ChiCTR1800015021 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1800015021 |
|---|---|
| Public title | Qinggan Jiangya capsule with songlingxuemaikang capsule in the treatment of primary hypertension (grade 1-2) (anger hyperactivity liver kidney yin deficiency syndrome) randomized, double-blind, multicenter clinical trial |
| Scientific title | Qinggan Jiangya capsule with songlingxuemaikang capsule in the treatment of primary hypertension (grade 1-2) (anger hyperactivity liver kidney yin deficiency syndrome) randomized, double-blind, multicenter clinical trial |
| Primary sponsor | Dongzhimen Hospital, Beijing University of Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | Other |
| Countries | China |
| Conditions | primary hypertension (grade 1-2) |
| Interventions | experimental group:Qinggan hypotensive capsule;control group:Songling Xuemaikang capsule |
| Registration date | Mar 1, 2018 |
| Target size | experimental group:360;control group:120 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: